Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...

BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced a lineup of presentations at the European Society for Medical Oncology (ESMO) ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named ...